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Olivier Nallet (1), Samia Arbaoui (1), Alain Grenier (2), Pierre Michaud
(1), Geoffroy Safrano (3), Jacky Sergent (1)
(1) Centre Hospitalier, Cardiologie, Montfermeil, France - (2) Centre
Hospitalier, Laboratoire de Biochimie, Montfermeil, France - (3) Centre
Hospitalier, Urgences, Montfermeil, France
Background: 
 
Cardiac troponin is the preferred biomarker of acute coro-
nary syndrom (ACS) and a reliable indicator of mortality in many other clin-
ical settings. It is routinely used for the assessment of patients admitted in
Emergency Departments (ED) even in the absence of clinical suspicion of
acute coronary syndrome (ACS). The clinical interest of such practice remains
to be determined.
 
Methods: 
 
295 consecutive patients admitted for various medical conditions
in our ED from January to June 2009 have been enrolled on the basis of high
troponin I level in their first blood sample (> 0.08 µg/l) and followed up for
survival until April 2010. Population was divided into two groups according
to the etiology of troponin elevation: group 1 when ACS; group 2 when no
criteria of ACS with or without alternative diagnosis for high troponin level.
 
Results:
 
 Final diagnosis for troponin elevation was ACS in 62 patients
(21%) and non ACS in 233 (79%). Forty six % had neither chest pain nor
ECG ischemic changes. Mean age was 69 +/-13 years in group 1 and 78+/- 13
in group 2.
In group 2, high troponin level was related to congestive heart failure or
arythmia in 41% of cases, sepsis 22%, acute respiratory failure 7%, stroke 5%,
miscellaneous 10% (myopericarditis n=3, Takotsubo n=5, rhabdomyolysis
n=4, pulmonary embolism n=5, haemorrhage n=6) and undetermined 15%. 
Hospital mortality was 12.5% in group 1 and 37 % in group 2. Overall sur-
vival at 12 months was 59% in group 2 compared to 85% for patients with
ACS. After multivariate analysis age, creatinine and BNP level were predic-
tors of survival. The variable ACS versus non ACS was not an independent
factor.
 
Conclusion: 
 
In ED, troponin is currently used in patients with of a low
probability of ACS. Troponin elevation is mainly due to medical conditions
other than ACS. When compared with the ACS group, the worse prognosis of
the non ACS patients appears to be strongly correlated to clinical variables
such as age, renal function and severe associated diseases. In conclusion risk
stratification of patients without ACS should first be based on clinical data
because troponin elevation elicits diagnosis confusion.
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Background:
 
 Cardiac troponin is the gold standard for the diagnosis and
risk stratification in acute coronary syndrome (ACS). Troponin elevation asso-
ciated with symptomatic paroxysmal reentrant supraventricular tachycardia
(PSVT) has been described in short series but long term prognosis has not
been yet reported. 
The aim of the present study was to evaluate the diagnostic and prognostic
value of troponin I elevation following PSVT. 
 
Methods and results:
 
 From January 2003 to September 2009, all consec-
utive patients (n=27, 52% females, median age 52 years) admitted for PSVT
and troponin I elevation (mean 0.42 µg/l, range: 0.19-5.9 ) were included. 
None of the patients had a history of CAD. Thirteen patients (48.1%) were
current smokers and 9 (33.3%) had no cardiovascular risk factor. All patients
had narrow QRS during PSVT and the aetiology was nodal reentrant tachy-
cardia in all except for one patient with preexcitation morphology in sinus
rhythm. 
Coronary angiogram has been performed in 25 patients. Twenty three had
angiographically normal coronary arteries. A single vessel disease (coronary
stenosis >50%) was found in 2 patients and maximal stress echocardiography
was normal in both patients. Two patients who declined coronary angiogram
had normal maximal stress echocardiography. 
During follow-up (median 43 months, range: 4- 82), none of the patients
experienced ACS or cardiac death. One of the patients died from cancer after
63 months of follow up. Recurrence of PSVT requiring medical intervention
occurred in 4 (14.8%) patients, atrial fibrillation in 3 (11%) patients and
radiofrequency catheter ablation of atrioventricular nodal reciprocating tachy-
cardia had been performed in 5 (18.5%) patients. 
 
Conclusions:
 
 Troponin I elevation following PSVT is common, not related
to obstructive CAD or plaque rupture and is not associated with adverse short
and long term prognosis.
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Purpose:
 
 Elevated troponin is frequent in acute ischaemic stroke but its
clinical implication remain unclear.The aim of this study is to describe preva-
lence, predictive factors and prognosis of patients with troponin elevation in
acute ischaemic stroke. A second end point was to diagnose a potential
ischaemic heart disease with cardiac magnetic resonance imaging (MRI) per-
formed in ten days after stroke.  
 
Methods:
 
 146 consecutive patients admitted for acute ischaemic stroke  in
our stroke unit were prospectively enrolled  between july and november 2009.
The blood troponin Ic was measured in the first two days after admission.
Clinical and biological data, stroke severity attested by national institute of
health stroke scale (NHISS) and in-hospital mortality were compared between
the two groups with and without troponin elevation.A cardiac MRI was per-
formed during hospitalization if troponin was positive. 
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Results:
 
  Serum troponin was elevated in 23 patients (15,7%). 
After multivariate analysis, 6 independent factors were associated with
troponin elevation : diabetes, 2 or more prior cardiovascular events, thrombol-
ysis, multiple localization of stroke, SGOT elevation and creatinin> 120 µmol/
L. Moreover, the 3 factors associated with in-hospital mortality after logistic
regression were troponin elevation (OR=2,56 [1,11-6,02] p=0,031), prior myo-
cardial infarction (OR=2,94 [1,16-7,95] p=0,002) and severe NIHSS at admis-
sion (OR=3,07 [1,35-7,39] p=0,007) 
Only 2 cardiac MRI have been readable because other patients were died
before the exam or were unable to have this exam because of stroke severity,
confusion or rapid atrial fibrillation. One of these patients had an acute myo-
cardial infarction diagnosed by cardiac MRI but a normal coronarography. 
 
Conclusion:
 
 Elevated troponin in acute ischaemic stroke is an independent
factor of in-hospital mortality. A troponin rise is more frequent in patients with
diabetes or prior cardiovascular events that’s why a screening of ischaemic heart
disease should be performed. Cardiac MRI can’t be widely performed at the early
stage of stroke, however it has been decisive for one patient in this study.
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The clinical significance of troponin release after coronary artery
bypass surgery : does the new universal definition of post-operative
myocardial infarction fit well with the long-term prognosis?
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Background:
 
 In the new (2007) universal definition for myocardial infarc-
tion (MI), the type-5 corresponded to MI after coronary revascularization, with
cardiac enzymes release >5x normal values (N) required after coronary artery
bypass graft (CABG) surgery. However, data on long-term prognosis of
patients with post-operative troponin release are scarce. 
 
Methods:
 
 We followed up 826 consecutive patients operated for CABG
between 1998 and 2002 in our institution. Post-operative troponin Ic (Tr-Ic)
release has been systematically monitored. The primary outcome was total
mortality. The secondary outcome was composite and combined: death, acute
coronary syndrome, stroke, coronary or peripheral revascularization. 
 
Results: 
 
Among the 693 men and 133 women (age 66.1 ± 9.3 yrs), post-
operative Tr-Ic peak >5xN, >10xN and >20xN were at 54.8%, 29.6% and
15.6%, respectively. During the follow-up period (6.5 ± 2.7 yrs), 146 (17.6%)
deceased, and 302 (36.6%) met the composite outcome. Only the survival
curves of those with Tr-Ic peak >10xN were significantly poorer than those
without type-5 MI (Figure). Adjusted for age, sex, use of beta-blockers and
statins, CVD risk factors, NYHA stage, LVEF <40%, number of bypasses, on/
off-pump surgery, atrial fibrillation, peripheral artery or chronic kidney dis-
ease, only Tr-Ic >20xN was associated with mortality, and Tr-Ic >10xN was
predictive for the composite outcome (table). 
 
Conclusions:
 
 This series with the longest follow-up ever published con-
firms the prognostic value of troponin release after CABG. However, the cur-
rent type-5 MI definition after CABG is not specific enough to stratify the
long-term post-operative prognosis. Higher thresholds are mandatory. 
 
(Voir tableau ci-dessous)
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Background:
 
 Microvascular obstruction (MVO) at the acute phase of
myocardial infarction (MI) is associated with greater myocardial damage, left
ventricular (LV) impairment and higher mortality. We aimed to evaluate
whether a correlation exists between plasma levels of cardiac troponin I (cTnI)
at the acute phase of MI and the extent of no-reflow as assessed by 3-T cardiac
magnetic resonance imaging (MRI). Secondly, we aimed to define a cut-off
value for cTnI predictive of no-flow. 
 
Methods:
 
 We included 51 consecutive patients with no previous history of
cardiovascular disease, and presenting for a first MI with or without ST eleva-
tion. Infarct size and extent of no-reflow were evaluated by 3-T MRI during
the acute phase using early and late hyperenhancement imaging at 3 and 15
minutes after injection of gadolinium. Extent of no-reflow at 15 minutes
(MVO) was measured and correlated with repeat doses of cTnI at 6, 12, 24,
48 and 72 hours after admission.
 
Results:
 
 Extent of MVO is significantly correlated to area under the curve
for cTnI (r=0.55, p<0.02), to the area under the ROC curve (p<0.005). After
analysis of ROC curves, a cut-off cTnI value >89 ng/mL at 6 hours seems to
best predict presence of early MVO with a sensitivity of 63% and specificity
of 88.2%.
 
Conclusion:
 
 A cut-off value of 89 ng/mL for cTnI seems to best predict
presence of MVO, which contributes to unfavourable long-term outcome.
Table- Post-CABG troponin and long-term prognosis (abstract 327). 
 Mortality Composite endpoint
Tr-Ic peak HR (95%CI) p HR (95%CI) p
< 5xN ref  ref  
5 to <10 xN 1.02 (0.65-1.61) ns 1.14 (0.84-1.55) ns
10 to <20 xN 1.33 (0.78-2.26) ns 1.45 (1.02-2.07) 0.04
20 xN 1.81 (1.14-2.88) 0.01 1.38 (1.00-1.94) 0.05
Figure- Survival according to post-CABG troponin
